Patent Issued to MediQuest Therapeutics, Inc. for its Compounds Targeting Inflammation and Undesirable Cell Proliferation

(Bothell, WA - 14 November 2005) MediQuest Therapeutics, Inc. announced today that it has been issued U.S. Patent No. 6,963,010 entitled "Hydrophobic Polyamine Analogs and Methods for Their Use".

This patent covers a broad class of novel compounds, which have immunomodulatory and antiproliferative properties. As pharmaceuticals, the compounds covered by the above patent may be used to treat inflammation and conditions characterized by excessive cell proliferation, such as in actinic keratosis, cutaneous lupus, and hair growth control.

According to Dr. Mark R. Burns, Executive Director of Chemistry at MediQuest and the patent's principal inventor, "The proprietary position established at MediQuest is ensuring a strong foundation on which the company is building a robust product pipeline. MediQuest, as a leader in the fields of immunology, polyamine chemistry and biology, is very pleased to receive this additional patent covering polyamine transport inhibitors which furthers its portfolio of intellectual property in a pioneering area of medicine." MediQuest has been granted three other patents for compounds controlling polyamine pathways in 2005 alone.

Dr. Fred Dechow, President & CEO of MediQuest, further adds, "The issuance of this important patent substantiates MediQuest's position and expertise in the polyamine field, supporting the Company's strategy to be either first or best in class with its products. The MediQuest drug candidates, combined with the Company's proprietary organo-gel topical delivery system, specifically designed to transport agents through thickened diseased skin and nails, are uniquely able to address unmet medical needs with minimal systemic side effects."

Actinic keratosis (AK) is a precancerous skin growth usually caused by sun exposure. AK commonly occurs in fairer skin, especially in the elderly and in residents of southern latitudes. About 5 million people in the United States suffer from AK with 20 percent aged 60 and above. The Company projects that it will begin clinical testing for this indication in 2006.

Cutaneous lupus (also known as Discoid lupus), which affects about 180,000 Americans, is an inflammation disease confined to and affecting the skin. The Company will be applying for orphan drug status for this indication with the FDA in 2006.

Another application, more along the line of cosmeceutical use, pertains to hair growth control. The compound may be added to current skin care products, such as underarm deodorant or body lotion and cream, to provide new and improved products. These products offer users additional convenience in their routines for personal care, such as less frequent shaving.